USD 102.9
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| MMSI | 0.8 | 6.1 | 3.9 | 8.0 | 18.8 | 32.0 | 84.7 | 180.4 | 543.1 | 12150 |
| S&P 500 | 1.0 | 1.8 | -0.9 | 2.7 | 7.3 | 26.5 | 31.0 | 80.1 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | MMSI |
| name | Merit Medical Systems, Inc. |
| price | 102.9 |
| changes percentage | 0.8132 |
| change | 0.83 |
| day low | 101.92 |
| day high | 103.23 |
| year high | 108.08 |
| year low | 70.7 |
| market cap | 5996950260 |
| price avg 50 | 101.1136 |
| price avg 200 | 90.4551 |
| exchange | NASDAQ |
| volume | 956020 |
| avg volume | 432216 |
| open | 102.01 |
| previous close | 102.07 |
| eps | 2.05 |
| pe | 50.2 |
| earnings announcement | 2025-02-25T21:00:00.000+0000 |
| shares outstanding | 58279400 |
| timestamp | 2025-01-17 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000856982 | |||
| revenue | 1257366000 | 1150981000 | 9.24 |
| gross profit | 583872000 | 519099000 | 12.48 |
| gross profit ratio | 0.46 | 0.45 | 2.96 |
| research and development expenses | 82728000 | 75510000 | 9.56 |
| operating expenses | 458727999 | 418035000 | 9.73 |
| interest income | 2456000 | 439000 | 459.45 |
| interest expense | 15511000 | 6339000 | 144.69 |
| ebitda | 231442000 | 181154000 | 27.76 |
| ebitdaratio | 0.18 | 0.17 | 8.83 |
| operating income | 123944000 | 87563000 | 41.55 |
| operating income ratio | 0.1 | 0.08 | 29.57 |
| net income | 94411000 | 74516000 | 26.70 |
| net income ratio | 0.08 | 0.06 | 15.98 |
| eps | 1.64 | 1.31 | 25.19 |
Revenue Growth: revenue increased to 1,257 million in 2023 from 1,151 million in 2022 representing a change of 9.24%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 584 million in 2023 from 519 million in 2022 representing a change of 12.48%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 83 million in 2023 from 76 million in 2022 representing a change of 9.56%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 231 million in 2023 from 181 million in 2022 representing a change of 27.76%. The increase in EBITDA indicates improved operational efficiency and profitability.
Net Income: Net income increased to 94 million in 2023 from 75 million in 2022 representing a change of 26.7%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 1.64 in 2023 from 1.64 in 2022 representing a change of 25.19%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 459 million in 2023 from 418 million in 2022 representing a change of 9.73%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Operating Income: Operating income decreased to 124 million in 2023 from 88 million in 2022 representing a change of 41.55%. The decrease in operating income indicates worse operational performance and decreased profitability.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000856982 | |||
| revenue | 339845000 | 337576000 | 0.67 |
| gross profit | 157535000 | 160316000 | -1.73 |
| gross profit ratio | 0.46 | 0.47 | -2.39 |
| research and development expenses | 20527000 | 20263000 | 1.30 |
| operating expenses | 120274000 | 114848000 | 4.72 |
| interest income | 6652000 | 7561000 | -12.02 |
| interest expense | 7501000 | 7679000 | -2.32 |
| ebitda | 73796000 | 81253000 | -9.18 |
| ebitdaratio | 0.22 | 0.21 | 1.11 |
| operating income | 37261000 | 45468000 | -18.05 |
| operating income ratio | 0.11 | 0.13 | -18.60 |
| net income | 28444000 | 35726000 | -20.38 |
| net income ratio | 0.08 | 0.11 | -20.91 |
| eps | 0.49 | 0.61 | -19.67 |
Revenue Growth: revenue increased to 340 million in 2024Q3 from 338 million in 2024Q2 representing a change of 0.67%. This indicates a sales growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 21 million in 2024Q3 from 20 million in 2024Q2 representing a change of 1.3%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Gross Profit: Gross Profit decreased to 158 million in 2024Q3 from 160 million in 2024Q2 representing a change of -1.73%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 120 million in 2024Q3 from 115 million in 2024Q2 representing a change of 4.72%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 74 million in 2024Q3 from 81 million in 2024Q2 representing a change of -9.18%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to 37 million in 2024Q3 from 45 million in 2024Q2 representing a change of -18.05%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to 28 million in 2024Q3 from 36 million in 2024Q2 representing a change of -20.38%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 0.49 in 2024Q3 from 0.49 in 2024Q2 representing a change of -19.67%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000856982 | |||
| total assets | 2325244000 | 1663966000 | 39.74 |
| total liabilities | 1123244000 | 519569000 | 116.19 |
| total equity | 1202000000 | 1144397000 | 5.03 |
| cash and cash equivalents | 587036000 | 58408000 | 905.06 |
| short term investments | 2100000 | 0 | NaN |
| long term investments | 19061000 | 15576000 | 22.37 |
| total current assets | 1108470000 | 529084000 | 109.51 |
| total non current assets | 1216774000 | 1134882000 | 7.22 |
| total current liabilities | 203564000 | 220645000 | -7.74 |
| total non current liabilities | 919680000 | 298924000 | 207.66 |
| common stock | 638150000 | 675174000 | -5.48 |
| retained earnings | 575184000 | 480773000 | 19.64 |
| total debt | 891359000 | 268750000 | 231.67 |
Total Assets: Total Assets increased to 2,325 million in 2023 from 1,664 million in 2022 representing a change of 39.74%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 1,202 million in 2023 from 1,144 million in 2022 representing a change of 5.03%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 587 million in 2023 from 58 million in 2022 representing a change of 905.06%. This indicates an increase in available liquid assets.
Short Term Investments: Short Term Investments increased to 2 million in 2023 from 0 million in 2022 representing a change of nan%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 1,108 million in 2023 from 529 million in 2022 representing a change of 109.51%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 204 million in 2023 from 221 million in 2022 representing a change of -7.74%. This indicates a lower short-term debt burden.
Retained Earnings: Retained Earnings increased to 575 million in 2023 from 481 million in 2022 representing a change of 19.64%. This indicates an accumulated profits.
Total Liabilities: Total Liabilities increased to 1,123 million in 2023 from 520 million in 2022 representing a change of 116.19%. This indicates an increase in overall liabilities.
Common Stock: Common Stock decreased to 638 in 2023 from 675 in 2022 representing a change of -5.48%. This indicates a decrease in ownership interest.
Total Debt: Total Debt increased to 891 million in 2023 from 269 million in 2022 representing a change of 231.67%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000856982 | |||
| total assets | 2378084000 | 2371839000 | 0.26 |
| total liabilities | 1054678000 | 1089394000 | -3.19 |
| total equity | 1323406000 | 1282445000 | 3.19 |
| cash and cash equivalents | 523128000 | 638712000 | -18.10 |
| short term investments | 2149000 | 254000 | 746.06 |
| long term investments | 32037000 | 31797000 | 0.75 |
| total current assets | 1078317000 | 1162546000 | -7.25 |
| total non current assets | 1299766999 | 1209293000 | 7.48 |
| total current liabilities | 201079000 | 186215000 | 7.98 |
| total non current liabilities | 853599000 | 903179000 | -5.49 |
| common stock | 669207000 | 658724000 | 1.59 |
| retained earnings | 667594000 | 639150000 | 4.45 |
| total debt | 819152000 | 871100000 | -5.96 |
Total Assets: Total Assets increased to 2,378 million in 2024Q3 from 2,372 million in 2024Q2 representing a change of 0.26%. Suggesting a growth in asset holdings.
Total Liabilities: Total Liabilities decreased to 1,055 million in 2024Q3 from 1,089 million in 2024Q2 representing a change of -3.19%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 1,323 million in 2024Q3 from 1,282 million in 2024Q2 representing a change of 3.19%. This indicates an increase in shareholders' equity.
Short Term Investments: Short Term Investments increased to 2 million in 2024Q3 from 0 million in 2024Q2 representing a change of 746.06%. This indicates an increase in short-term investment holdings.
Common Stock: Common Stock increased to 669 in 2024Q3 from 659 in 2024Q2 representing a change of 1.59%. This indicates an increase in ownership interest.
Retained Earnings: Retained Earnings increased to 668 million in 2024Q3 from 639 million in 2024Q2 representing a change of 4.45%. This indicates an accumulated profits.
Total Debt: Total Debt decreased to 819 million in 2024Q3 from 871 million in 2024Q2 representing a change of -5.96%. This indicates a reduction in overall debt burden.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 523 million in 2024Q3 from 639 million in 2024Q2 representing a change of -18.1%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 1,078 million in 2024Q3 from 1,163 million in 2024Q2 representing a change of -7.25%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 201 million in 2024Q3 from 186 million in 2024Q2 representing a change of 7.98%. This indicates a higher short-term debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000856982 | |||
| net change in cash | 528586000 | -7192000 | 7449.64 |
| operating cash flow | 145151000 | 114291000 | 27.00 |
| free cash flow | 108450000 | 69262000 | 56.58 |
| capital expenditure | -36701000 | -45029000 | 18.49 |
| depreciation and amortization | 101292000 | 92198000 | 9.86 |
| deferred income tax | -12643000 | -14924000 | 15.28 |
| stock based compensation | 21333000 | 18042000 | 18.24 |
| accounts payables | -7297000 | 12661000 | -157.63 |
| inventory | 0 | -47929000 | 100.00 |
| acquisitions net | -137847000 | -8287000 | -1563.41 |
| investments in property plant and equipment | -36701000 | -45029000 | 18.49 |
| net cash used for investing activites | -175347000 | -57397000 | -205.50 |
| debt repayment | 619579000 | -44938000 | 1478.74 |
| common stock issued | 15584000 | 20070000 | -22.35 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 559266000 | -60260000 | 1028.09 |
| cash at end of period | 589144000 | 60558000 | 872.86 |
| accounts receivables | 0 | -15116000 | 100.00 |
| cash at beginning of period | 60558000 | 67750000 | -10.62 |
Net Change in Cash: Net Change in Cash increased to 529 million in 2023 from -7 million in 2022 representing a change of 7449.64%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 145 million in 2023 from 114 million in 2022 representing a change of 27.0%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 108 million in 2023 from 69 million in 2022 representing a change of 56.58%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables decreased to 7 million in 2023 from 13 million in 2022 representing a change of -157.63%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to -37 million in 2023 from -45 million in 2022 representing a change of 18.49%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to -13 million in 2023 from -15 million in 2022 representing a change of 15.28%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation increased to 21 million in 2023 from 18 million in 2022 representing a change of 18.24%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to 0 in 2023 from -15 million in 2022 representing a change of 100.0%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0000856982 | |||
| operating cash flow | 47333000 | 68506000 | -30.91 |
| free cash flow | 37412000 | 57164000 | -34.55 |
| capital expenditure | -9921000 | -11342000 | 12.53 |
| depreciation and amortization | 29383000 | 27032000 | 8.70 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 6713000 | 7011000 | -4.25 |
| accounts receivables | -10719000 | -2719000 | -294.23 |
| accounts payables | 607000 | 7052000 | -91.39 |
| inventory | -5963000 | 3501000 | -270.32 |
| acquisitions net | -105250000 | -5147000 | -1944.88 |
| investments in property plant and equipment | -9921000 | -11342000 | 12.53 |
| net cash used for investing activites | -115668000 | -16486999 | -601.57 |
| debt repayment | -52000000 | 0 | NaN |
| common stock issued | 4493000 | 3201000 | 40.36 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -47574000 | 3137000 | -1616.54 |
| net change in cash | -113435000 | 54725000 | -307.28 |
| cash at end of period | 525277000 | 638712000 | -17.76 |
| cash at beginning of period | 638712000 | 583987000 | 9.37 |
Net Change in Cash: Net Change in Cash decreased to -113 million in 2024Q3 from 55 million in 2024Q2 representing a change of -307.28%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to 47 million in 2024Q3 from 69 million in 2024Q2 representing a change of -30.91%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 37 million in 2024Q3 from 57 million in 2024Q2 representing a change of -34.55%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -10 million in 2024Q3 from -11 million in 2024Q2 representing a change of 12.53%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation decreased to 7 million in 2024Q3 from 7 million in 2024Q2 representing a change of -4.25%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 1 million in 2024Q3 from 7 million in 2024Q2 representing a change of -91.39%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -11 million in 2024Q3 from -3 million in 2024Q2 representing a change of -294.23%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 21.83 | 20.26 | 7.75 |
| net income per share | 1.64 | 1.31 | 24.97 |
| operating cash flow per share | 2.52 | 2.01 | 25.27 |
| free cash flow per share | 1.88 | 1.22 | 54.44 |
| cash per share | 10.23 | 1.03 | 894.87 |
| book value per share | 20.87 | 20.15 | 3.60 |
| tangible book value per share | 8.58 | 8.96 | -4.24 |
| shareholders equity per share | 20.87 | 20.15 | 3.60 |
| interest debt per share | 15.75 | 4.84 | 225.16 |
| market cap | 4374764280 | 4011639720.0 | 9.05 |
| enterprise value | 4679087280 | 4221981720.0 | 10.83 |
| pe ratio | 46.34 | 53.84 | -13.93 |
| price to sales ratio | 3.48 | 3.49 | -0.18 |
| pocfratio | 30.14 | 35.1 | -14.13 |
| pfcf ratio | 40.34 | 57.92 | -30.35 |
| pb ratio | 3.64 | 3.51 | 3.83 |
| ptb ratio | 3.64 | 3.51 | 3.83 |
| ev to sales | 3.72 | 3.67 | 1.45 |
| enterprise value over ebitda | 20.22 | 23.31 | -13.25 |
| ev to operating cash flow | 32.24 | 36.94 | -12.74 |
| ev to free cash flow | 43.15 | 60.96 | -29.22 |
| earnings yield | 0.02 | 0.02 | 16.18 |
| free cash flow yield | 0.02 | 0.02 | 43.58 |
| debt to equity | 0.74 | 0.23 | 215.77 |
| debt to assets | 0.38 | 0.16 | 137.35 |
| net debt to ebitda | 1.31 | 1.16 | 13.24 |
| current ratio | 5.45 | 2.4 | 127.09 |
| interest coverage | 7.99 | 13.81 | -42.15 |
| income quality | 1.54 | 1.53 | 0.24 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.07 | 0.07 | 0.29 |
| intangibles to total assets | 0.3 | 0.38 | -20.29 |
| capex to operating cash flow | 0.25 | 0.39 | -35.82 |
| capex to revenue | 0.03 | 0.04 | -25.39 |
| capex to depreciation | 0.36 | 0.49 | -25.81 |
| stock based compensation to revenue | 0.02 | 0.02 | 8.24 |
| graham number | 27.75 | 24.38 | 13.78 |
| roic | 0.05 | 0.05 | -8.51 |
| return on tangible assets | 0.06 | 0.07 | -19.44 |
| graham net net | -4.17 | -3.42 | -21.93 |
| working capital | 904906000 | 308439000 | 193.38 |
| tangible asset value | 493877000 | 508704000 | -2.91 |
| net current asset value | -14774000 | 9515000 | -255.27 |
| invested capital | 2059599000 | 1392370000 | 47.92 |
| average receivables | 183854500 | 175644500 | 4.67 |
| average payables | 67224000 | 62064000 | 8.31 |
| average inventory | 284931000 | 243956500 | 16.80 |
| days sales outstanding | 54.94 | 56.59 | -2.91 |
| days payables outstanding | 35.74 | 39.57 | -9.68 |
| days of inventory on hand | 164.68 | 153.65 | 7.18 |
| receivables turnover | 6.64 | 6.45 | 3.00 |
| payables turnover | 10.21 | 9.22 | 10.72 |
| inventory turnover | 2.22 | 2.38 | -6.70 |
| roe | 0.08 | 0.07 | 20.63 |
| capex per share | 0.64 | 0.79 | -19.61 |
ROE:
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to 46.34 on 2023-12-31 from 53.84 on 2022-12-31, representing a change of -13.93%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 5.45 on 2023-12-31 from 2.40 on 2022-12-31, representing a change of 127.09%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.74 on 2023-12-31 from 0.23 on 2022-12-31, representing a change of 215.77%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| MMSI | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 5.84 | 5.81 | 0.51 |
| net income per share | 0.49 | 0.61 | -20.51 |
| operating cash flow per share | 0.81 | 1.18 | -31.02 |
| free cash flow per share | 0.64 | 0.98 | -34.66 |
| cash per share | 9.02 | 10.99 | -17.92 |
| book value per share | 22.73 | 22.06 | 3.03 |
| tangible book value per share | 9.48 | 10.28 | -7.81 |
| shareholders equity per share | 22.73 | 22.06 | 3.03 |
| interest debt per share | 14.2 | 15.12 | -6.08 |
| market cap | 5754969730 | 4979023960 | 15.58 |
| enterprise value | 6050993730 | 5211411960 | 16.11 |
| pe ratio | 50.58 | 34.84 | 45.18 |
| price to sales ratio | 16.93 | 14.75 | 14.81 |
| pocfratio | 121.58 | 72.68 | 67.29 |
| pfcf ratio | 153.83 | 87.1 | 76.61 |
| pb ratio | 4.35 | 3.88 | 12.01 |
| ptb ratio | 4.35 | 3.88 | 12.01 |
| ev to sales | 17.81 | 15.44 | 15.34 |
| enterprise value over ebitda | 82.0 | 64.14 | 27.84 |
| ev to operating cash flow | 127.84 | 76.07 | 68.05 |
| ev to free cash flow | 161.74 | 91.17 | 77.41 |
| earnings yield | 0.0 | 0.01 | -31.12 |
| free cash flow yield | 0.01 | 0.01 | -43.38 |
| debt to equity | 0.62 | 0.68 | -8.87 |
| debt to assets | 0.34 | 0.37 | -6.21 |
| net debt to ebitda | 4.01 | 2.86 | 40.26 |
| current ratio | 5.36 | 6.24 | -14.10 |
| interest coverage | 4.97 | 5.92 | -16.11 |
| income quality | 1.66 | 1.92 | -13.22 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.06 | 0.06 | 0.63 |
| intangibles to total assets | 0.32 | 0.29 | 12.37 |
| capex to operating cash flow | 0.21 | 0.17 | 26.60 |
| capex to revenue | 0.03 | 0.03 | -13.11 |
| capex to depreciation | 0.34 | 0.42 | -19.53 |
| stock based compensation to revenue | 0.02 | 0.02 | -4.89 |
| graham number | 15.8 | 17.46 | -9.50 |
| roic | 0.01 | 0.02 | -18.06 |
| return on tangible assets | 0.02 | 0.02 | -16.39 |
| graham net net | -3.68 | -2.64 | -39.47 |
| working capital | 877238000 | 976331000 | -10.15 |
| tangible asset value | 551794000 | 597590000 | -7.66 |
| net current asset value | 23639000 | 73152000 | -67.69 |
| invested capital | 2107370000 | 2117028000 | -0.46 |
| average receivables | 205351500 | 194729000 | 5.46 |
| average payables | 58190500 | 51975000 | 11.96 |
| average inventory | 304375500 | 300478500 | 1.30 |
| days sales outstanding | 56.5 | 52.62 | 7.37 |
| days payables outstanding | 30.02 | 28.22 | 6.39 |
| days of inventory on hand | 153.3 | 151.42 | 1.24 |
| receivables turnover | 1.59 | 1.71 | -6.87 |
| payables turnover | 3.0 | 3.19 | -6.01 |
| inventory turnover | 0.59 | 0.59 | -1.23 |
| roe | 0.02 | 0.03 | -22.85 |
| capex per share | 0.17 | 0.2 | -12.67 |
ROE: Return on Equity (ROE) decreased to 0.02 on 2024-09-30 Q3 from 0.03 on 2024-06-30 Q2, representing a change of -22.85%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 5.36 on 2024-09-30 Q3 from 6.24 on 2024-06-30 Q2, representing a change of -14.10%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 50.58 on 2024-09-30 Q3 from 34.84 on 2024-06-30 Q2, representing a change of 45.18%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.62 on 2024-09-30 Q3 from 0.68 on 2024-06-30 Q2, representing a change of -8.87%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is 41.1 which is lower than current price 102.9, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-17 12:41:14
Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?
Sentiment: Positive
Publish Date: 2025-01-17 10:46:16
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Sentiment: Positive
Publish Date: 2025-01-15 11:36:11
MMSI's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
Sentiment: Positive
Publish Date: 2025-01-13 19:10:00
* Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable GAAP financial measure is included under the heading “Non-GAAP Financial Measure” below.
Sentiment: Positive
Publish Date: 2025-01-02 13:54:37
Merit Medical (MMSI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Sentiment: Positive
Publish Date: 2025-01-02 12:20:28
Merit Medical's strong product portfolio raises optimism about the stock.
Sentiment: Positive
Publish Date: 2025-01-01 12:51:07
Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Merit Medical (MMSI). But which of these two companies is the best option for those looking for undervalued stocks?
Sentiment: Positive
Publish Date: 2025-01-01 10:51:16
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Sentiment: Positive
Publish Date: 2024-12-23 12:31:07
MMSI announces FDA approval for the WRAPSODY Cell-Impermeable Endoprosthesis.
Sentiment: Positive
Publish Date: 2024-12-20 09:15:00
SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, Merit can begin commercialization of the device in the USA in 2025.
Sentiment: Positive
Publish Date: 2024-12-16 16:00:00
SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI) (“Merit” or the “Company”), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025.
Sentiment: Positive
Publish Date: 2024-12-16 10:46:37
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Sentiment: Positive
Publish Date: 2024-12-13 03:15:24
Becton, Dickinson, BD, McKesson, Cardinal Health and Merit Medical Systems have been highlighted in this Industry Outlook article.
Sentiment: Positive
Publish Date: 2024-12-12 09:46:09
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These are BDX, MCK, CAH and MMSI.
Sentiment: Positive
Publish Date: 2024-11-29 12:46:27
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Merit Medical (MMSI) or West Pharmaceutical Services (WST). But which of these two stocks presents investors with the better value opportunity right now?
Sentiment: Positive
Publish Date: 2024-11-26 12:06:21
The significant improvement in patency rates for AVG patients via Merit Medical's WRAPSODY device is expected to enhance patients' vascular access survival.
Sentiment: Positive
Publish Date: 2024-11-25 10:25:00
Dublin, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The "Fundus Camera Market Global Forecast Report by Product Type, End-User, Countries and Company Analysis 2025-2033" report has been added to ResearchAndMarkets.com's offering. The Fundus Camera market was valued at US$459.40 million in 2024 and is anticipated to hit US$665.85 million by 2033 from 2025 to 2033 with a compound annual growth rate of 4.21%. The primary reason for this growth stems from the demand for more developed diagnostics within the eyes, mainly because of retinal disorders that have been on the rise across the globe. A fundus camera is a medical imaging device specific in the application of ophthalmology to capture high resolution images of the internal eye, with emphasis on the retina, optic disc, and macula. It illuminates and photographs the retina through the pupil to provide critical details necessary for diagnostics and management procedures in various eye conditions. Fundus cameras thus play an instrumental role in detecting retinal disorders including diabetic retinopathy, glaucoma, age-related macular degeneration, and retinal detachment. These conditions often progress in a gradual manner but may go unnoticed until they start impairing vision seriously. In that case, early detection via the use of fundus photography will give time to intervene before more serious vision loss takes place. There are mydriatic, non-mydratic, and hybrid types available, and there are also handheld or portable types for easier access. Apart from diagnosis, follow up of disease progression and effectiveness of the treatment being provided makes fundus imaging a tool more essential in eye care. Growth Drivers for the Fundus Camera Market
Sentiment: Positive
Publish Date: 2024-11-25 09:15:00
WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial
Sentiment: Positive
Publish Date: 2024-11-21 13:46:13
Merit Medical (MMSI) could produce exceptional returns because of its solid growth attributes.
Sentiment: Positive
Publish Date: 2024-11-20 09:05:18
MMSI shows strong growth momentum with a robust product portfolio and recent acquisitions, positioning itself well in competitive healthcare markets.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
